Table 2.
Univariate and multivariate survival analysis for all patients (n=126)
| Characteristics | Comparisons | Univariate survival analysis | Multivariate survival analysis | ||
|---|---|---|---|---|---|
| Median postsurgical survival in months (95% CI) | p value | HR (95% CI) | p value | ||
| Gender | Male vs Female | 35.1 (27.0-43.1) vs 63.4 (29.3-97.4) | 0.030* | 1.3 (0.8-2.4) (5%) 1.3 (0.8-2.3) (25%) 1.5 (0.9-2.5) (50%) |
0.297 (5%) 0.344 (25%) 0.166 (50%) |
| Age | <60 years vs ≥60 years | 44.1 (29.0-59.2) vs 35.3 (19.1-51.4) | 0.274 | ||
| Smoking | Never vs Ever | 48.0 (26.7-69.2) vs 33.5 (23.9-43.0) | 0.070 | ||
| Histological types | AD vs Non-AD | 49.1 (28.1-70.0) vs 33.5 (26.4-40.5) | 0.064 | ||
| Tumor grade | Low differentiation vs Moderate and high differentiations | 30.8 (19.9-41.8) vs 46.1 (34.4-57.8) | 0.015* | 1.3 (0.8-2.2) (5%) 1.3 (0.8-2.1) (25%) 1.3 (0.8-2.1) (50%) |
0.258 (5%) 0.378 (25%) 0.333 (50%) |
| Clinical stage | I-II vs IIIA | 81.3 (NA) vs 33.5 (22.8-44.1) | 0.002* | 0.5 (0.3-0.8) (5%) 0.5 (0.3-0.8) (25%) 0.5 (0.3-0.9) (50%) |
0.007* (5%) 0.004* (25%) 0.012* (50%) |
| PD-L1 expression in TC (5%) | +ve vs -ve | 27.7 (18.2-37.1) vs 51.9 (33.9-70.0) | 0.039* | 1.5 (0.9-2.5) | 0.080 |
| PD-L1 expression in TC (25%) | +ve vs -ve | 20.5 (5.4-35.7) vs 49.1 (30.7-67.5) | <0.001* | 2.4 (1.4-4.2) | 0.001* |
| PD-L1 expression in TC (50%) | +ve vs -ve | 14.7 (0-33.1) vs 45.3 (33.8-56.8) | 0.003* | 2.4 (1.1-4.7) | 0.021* |
| Presence of TIL | With vs Without | 39.6 (31.8-47.4) vs 63.4 (28.3-98.4) | 0.099 | ||
| EGFR | +ve vs -ve | 45.3 (NA) vs 38.5 (26.7-50.3) | 0.096 | ||
| KRAS | +ve vs -ve | 14.7 (NA) vs 41.1 (32.2-50.1) | 0.706 | ||
*p<0.05.
Abbreviations: AD: adenocarcinoma; CI: confidence interval; EGFR: epidermal growth factor receptor; HR: hazard ratio; KRAS: Kirsten rat sarcoma viral oncogene; NSCLC: non-small cell lung cancer; TC: tumor cells; TIL: tumor infiltrating lymphocytes.
+ve and -ve represent positive and negative results.